From animal to human: pros and cons of different translational dosimetry methodologies to predict human dosimetry and select first-in-human (FiH) escalation starting activity

lutetium Lu 177 rofapitide tetraxetan (AAA614) - Novartis

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis

Lutathera (lutetium Lu 177 dotatate) - Novartis

https://www.xcdsystem.com/snmmi/program/UtDKfSi/index.cfm?pgid=3058&sid=53915&mobileappid=5385900000

Edd Kitchen; Suzanne Gaudet , PhD; Gabriele Birindelli, PhD; Giulia Tamborino, PhD; Lars Blumenstein; Florence Catherine Yvonne Hourcade-Potelleret, PhD; Shefali Kakar, PhD; Birgit Schoeberl, PhD; Ufuk Olgac

May 26, 2026